Prostate cancer in Pennsylvania: The role of older age at diagnosis, aggressiveness, and environmental risk factors on treatment and mortality using data from the Pennsylvania Cancer Registry.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
05 2020
Historique:
received: 10 11 2019
revised: 27 02 2020
accepted: 28 02 2020
pubmed: 27 3 2020
medline: 4 9 2021
entrez: 27 3 2020
Statut: ppublish

Résumé

To assess: (a) cancer treatment in prostate cancer survivors (PCS) by age at diagnosis (ADx) and prostate cancer (PC) aggressiveness; (b) potential impact on PC mortality; and (c) these results in the context of environmental/behavioral risk factors on PCS in Pennsylvania. Prostate cancer survivors ages ≥40 years were identified from the 2004-2014 Pennsylvania Cancer Registry (PCR). Demographic/clinical descriptors and PC treatment were extracted from PCR. Prostate cancer aggressiveness was defined by clinical/pathologic Gleason score and tumor stage. Logistic and Cox regression analyses tested associations between treatment received and PC-specific mortality. County-level data from the Pennsylvania BRFSS were used to estimate cancer-related behavioral risk factors (eg, smoking, physical inactivity, fruit/vegetable consumption [FV], alcohol use) and used as covariates. There were 90 694 PCS ages 40-105 years (mean age = 66.19 years, SD = 9.25) included. Most were non-Hispanic white men (83%). Prostate cancer survivors ≥75 years were least likely to receive any treatment but men ages 65-74 were more likely to receive combined therapies (OR = 1.47; 95% CI 1.28, 1.69) vs PCS ages 40-54 years, controlling for covariates. Prostate cancer survivors 55-75+ with aggressive PC who received any treatment vs no definitive treatment had significantly reduced mortality. Men from counties with high obesity and smoking rates were significantly less likely to receive any treatment than men living in counties with lower rates of these risk factors. Prostate cancer survivors who lived in counties with high rates of physical inactivity and had high rates of sufficient FV consumption were slightly more likely to receive cancer treatment vs no definitive treatment compared to men who lived in counties with high rates of physical activity and lower FV consumption. We observed a general age-related decline in receipt of treatment. Prostate cancer survivors ages ≥75 years were significantly less likely to get any cancer treatment compared to younger PCS. However, most men with more aggressive disease who received any treatment had greatly reduced PC mortality, regardless of age. Considering environmental/behavioral risk factors may attenuate PC risk and inform treatment options.

Sections du résumé

BACKGROUND
To assess: (a) cancer treatment in prostate cancer survivors (PCS) by age at diagnosis (ADx) and prostate cancer (PC) aggressiveness; (b) potential impact on PC mortality; and (c) these results in the context of environmental/behavioral risk factors on PCS in Pennsylvania.
METHODS
Prostate cancer survivors ages ≥40 years were identified from the 2004-2014 Pennsylvania Cancer Registry (PCR). Demographic/clinical descriptors and PC treatment were extracted from PCR. Prostate cancer aggressiveness was defined by clinical/pathologic Gleason score and tumor stage. Logistic and Cox regression analyses tested associations between treatment received and PC-specific mortality. County-level data from the Pennsylvania BRFSS were used to estimate cancer-related behavioral risk factors (eg, smoking, physical inactivity, fruit/vegetable consumption [FV], alcohol use) and used as covariates.
RESULTS
There were 90 694 PCS ages 40-105 years (mean age = 66.19 years, SD = 9.25) included. Most were non-Hispanic white men (83%). Prostate cancer survivors ≥75 years were least likely to receive any treatment but men ages 65-74 were more likely to receive combined therapies (OR = 1.47; 95% CI 1.28, 1.69) vs PCS ages 40-54 years, controlling for covariates. Prostate cancer survivors 55-75+ with aggressive PC who received any treatment vs no definitive treatment had significantly reduced mortality. Men from counties with high obesity and smoking rates were significantly less likely to receive any treatment than men living in counties with lower rates of these risk factors. Prostate cancer survivors who lived in counties with high rates of physical inactivity and had high rates of sufficient FV consumption were slightly more likely to receive cancer treatment vs no definitive treatment compared to men who lived in counties with high rates of physical activity and lower FV consumption.
CONCLUSIONS
We observed a general age-related decline in receipt of treatment. Prostate cancer survivors ages ≥75 years were significantly less likely to get any cancer treatment compared to younger PCS. However, most men with more aggressive disease who received any treatment had greatly reduced PC mortality, regardless of age. Considering environmental/behavioral risk factors may attenuate PC risk and inform treatment options.

Identifiants

pubmed: 32212232
doi: 10.1002/cam4.3003
pmc: PMC7221418
doi:

Substances chimiques

Antineoplastic Agents 0
Antineoplastic Agents, Hormonal 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3623-3633

Subventions

Organisme : NIH HHS
ID : KL2 TR000126
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002014
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR033184
Pays : United States

Informations de copyright

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

J Clin Oncol. 2014 Aug 20;32(24):2523-30
pubmed: 25071137
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):561-70
pubmed: 23535024
Urologe A. 2012 Oct;51(10):1368-74
pubmed: 23053031
JAMA Netw Open. 2018 Oct 5;1(6):e183146
pubmed: 30646225
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Eur Urol. 2017 Oct;72(4):521-531
pubmed: 28089304
PLoS One. 2017 Mar 27;12(3):e0174548
pubmed: 28346484
Prostate. 2011 Jun 15;71(9):985-97
pubmed: 21541975
Urol Oncol. 2010 Nov-Dec;28(6):628-34
pubmed: 19117769
J Health Care Poor Underserved. 2011;22(4 Suppl):187-99
pubmed: 22102314
Lancet Oncol. 2014 Aug;15(9):e404-14
pubmed: 25079103
J Clin Oncol. 2014 Nov 1;32(31):3568-74
pubmed: 25273035
BMC Med Res Methodol. 2013 Mar 24;13:49
pubmed: 23522349
Psychol Sci. 2012 Jun;23(6):547-53
pubmed: 22555966
Ann Intern Med. 2012 Jul 17;157(2):120-34
pubmed: 22801674
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):882-9
pubmed: 24526287
Prostate Cancer Prostatic Dis. 2012 Dec;15(4):374-9
pubmed: 22710832
J Clin Oncol. 2011 Jan 10;29(2):235-41
pubmed: 21135285
Cancer. 2013 Mar 1;119(5):1050-7
pubmed: 23096263
Prostate Cancer. 2011;2011:846263
pubmed: 22111000
JAMA. 2011 Jun 22;305(24):2548-55
pubmed: 21693743
J Oncol Pract. 2018 Oct;14(10):618-624
pubmed: 30199312
Ann Oncol. 2017 Feb 1;28(2):400-407
pubmed: 27831506
J Natl Compr Canc Netw. 2007 Aug;5(7):709-13
pubmed: 17692176
CA Cancer J Clin. 2014 Jul-Aug;64(4):225-49
pubmed: 24916760
J Pain Symptom Manage. 2012 Jan;43(1):96-110
pubmed: 21640547
J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9
pubmed: 19720969
Health Serv Res. 2018 Dec;53(6):4310-4331
pubmed: 29845634
N Engl J Med. 2013 Jan 31;368(5):436-45
pubmed: 23363497
Cancer Med. 2020 May;9(10):3623-3633
pubmed: 32212232
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Rural Health. 2005 Winter;21(1):39-47
pubmed: 15667008
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36
pubmed: 27371756
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):255-64
pubmed: 25417239

Auteurs

Shirley M Bluethmann (SM)

The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Penn State Cancer Institute, Hershey, PA, USA.

Ming Wang (M)

The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Penn State Cancer Institute, Hershey, PA, USA.

Emily Wasserman (E)

The Pennsylvania State University College of Medicine, Hershey, PA, USA.

Chixiang Chen (C)

The Pennsylvania State University College of Medicine, Hershey, PA, USA.

Nicholas G Zaorsky (NG)

The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Penn State Cancer Institute, Hershey, PA, USA.

Raymond J Hohl (RJ)

The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Penn State Cancer Institute, Hershey, PA, USA.

Alicia C McDonald (AC)

The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Penn State Cancer Institute, Hershey, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH